Data Monitoring Committees Are Useful For High-Risk Phase I/II Trials – FDA

FDA is strongly recommending data monitoring committees for early-phase clinical trials where the investigator is also the sponsor or where subjects may be placed at unusually high risk, a draft guidance on data monitoring committees states